Based on these observations, it is important to perform combination treatment approaches such as FLT3 inhibitors (midostaurin or gliteritinib) in combination with JAK-family kinase inhibitors (ruxolitinib or momelotinib) to achieve better therapeutic response in AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.